{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T04:45:28Z","timestamp":1720068328709},"reference-count":22,"publisher":"The Japan Geriatrics Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn. j. geriat","Nippon Ronen Igakkai Zasshi","Nihon Ronen Igakkai Zasshi","Jpn J Geriat"],"published-print":{"date-parts":[[2019,1,25]]},"DOI":"10.3143\/geriatrics.56.43","type":"journal-article","created":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T17:39:16Z","timestamp":1549993156000},"page":"43-50","source":"Crossref","is-referenced-by-count":3,"title":["Clinical characteristics of bullous pemphigoid in elderly patients with type 2 diabetes mellitus: The association with the use of dipeptidyl peptidase-4 inhibitors"],"prefix":"10.3143","volume":"56","author":[{"given":"Remi","family":"Kodera","sequence":"first","affiliation":[{"name":"Department of Diabetes, Metabolism, and Endocrinology, Tokyo Metropolitan Geriatric Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Chiba","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Metabolism, and Endocrinology, Tokyo Metropolitan Geriatric Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Metabolism, and Endocrinology, Tokyo Metropolitan Geriatric Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rieko","family":"Miyazawa","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tokyo Metropolitan Geriatric Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoji","family":"Tanei","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tokyo Metropolitan Geriatric Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seijiro","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Metabolism, and Endocrinology, Tokyo Metropolitan Geriatric Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Metabolism, and Endocrinology, Tokyo Metropolitan Geriatric Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Araki","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Metabolism, and Endocrinology, Tokyo Metropolitan Geriatric Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1704","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Bernard P, Vaillant L, Labeille B, Bedane C, Arbeille B, Denoeux JP, et al.: Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol 1995; 131: 48-52.","DOI":"10.1001\/archderm.1995.01690130050009"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Zillikens D, Weber S, Roth A, et al.: Incidence of Autoimmune Subepidermal Blistering Dermatoses in a Region of Central Germany. Arch Dermatol 1995; 131: 957-958.","DOI":"10.1001\/archderm.131.8.957"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Joly P, Roujeau JC, Benichou J, Delaporte E, D'lncan M, Dreno B, et al.: A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol 2009; 129: 1681-1687.","DOI":"10.1038\/jid.2008.412"},{"key":"4","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000106574","volume":"215","author":"N Cordel","year":"2007","unstructured":"4) Cordel N, Chosidow O, Hellot MF, Delaporte E, Lok C, Vaillant L, et al.: Neurological disorders in patients with bullous pemphigoid. Dermatology 2007; 215: 187-191.","journal-title":"Dermatology","ISSN":"http:\/\/id.crossref.org\/issn\/1018-8665","issn-type":"print"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Adam BA: Bullous diseases in Malaysia: epidemiology and natural history. Int J Dermatol 1992; 31: 42-45.","DOI":"10.1111\/j.1365-4362.1992.tb03519.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Jung M, Kippes W, Messer G, Zillikens D, Rzany B: Increaed risk of bullous pemphigoid in male and very old patients: A population-based study on incidence. J Am Acad Dermatol 1999; 41: 266-268.","DOI":"10.1016\/S0190-9622(99)70061-7"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Colbert RL, Allen DM, Eastwood D, Fairley JA: Mortality rate of bullous pemphigoid in a US medical center. J Invest Dermatol 2004; 122: 1091-1095.","DOI":"10.1111\/j.0022-202X.2004.22504.x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Roujeau JC, Lok C, Bastuji-Garin S, Mhalla S, Enginger V, Bernard P: High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol 1998; 134: 465-469.","DOI":"10.1001\/archderm.134.4.465"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Chuang TY, Korkij W, Soltani K, Clayman J, Cook J: Increased frequency of diabetes mellitus in patients with bullous pemphigoid: a case-control study. J Am Acad Dermatol 1984; 11: 1099-1102.","DOI":"10.1016\/S0190-9622(84)70266-0"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Bastuji-Garin S, Joly P, Lemordant P, Sparsa A, Bedane C, Delaporte E, et al.: Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Investigative Dermatology 2011; 131: 637-643.","DOI":"10.1038\/jid.2010.301"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Skandalis K, Spirova M, Gaitanis G, Tsartsarakis A, Bassukas ID: Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermatol Venereol 2012; 26: 249-253.","DOI":"10.1111\/j.1468-3083.2011.04062.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Aouidad I, Fite C, Marinho E, Deschamps L, Crickx B, Descamps V: A case report of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. JAMA Dermatol 2013; 149: 243-245.","DOI":"10.1001\/jamadermatol.2013.1073"},{"key":"13","unstructured":"13) Guideline on the Diagnosis and Treatment of Autoimmune bullous diseases -Pemphigoid. Developed by the Guideline Subcommittee of the European Dermatology Forum 2017."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Kasperkiewicz M, Zillikens D: The pathophysiology of bullous pemphigoid. Clin Rev Allergy Immunol 2007; 33: 67-77.","DOI":"10.1007\/s12016-007-0030-y"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Izumi K, Nishie W, Mai Y, Wada M, Natsuga K, Ujiie H, et al.: Autoantibody Profile Differentiates between Inflammatory and Noninflammatory Bullous Pemphigoid. J Invest Dermatol 2016; 136: 2201-2210.","DOI":"10.1016\/j.jid.2016.06.622"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) B\u00e9n\u00e9 J, Moulis G, Bennani I, Auffret M, Coupe P, Babai S, et al.: Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database. Br J Dermatol 2016; 175: 296-301.","DOI":"10.1111\/bjd.14601"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Attaway A, Mersfelder TL, Vaishnav S, Baker JK: Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature. J Dermatol Case Rep 2014; 8: 24-28.","DOI":"10.3315\/jdcr.2014.1166"},{"key":"18","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","volume":"381","author":"E Schmidt","year":"2013","unstructured":"18) Schmidt E, Zillikens D: Pemphigoid diseases. Lancet 2013; 381: 320-332.","journal-title":"The Lancet","ISSN":"http:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"19","unstructured":"19) Ujiie H, Muramatsu K, Mushiroda T, Ozeki T, Miyoshi H, Iwata H, et al.: HLA-DQB1*03: 01 as a Biomarker for Genetic Susceptibility to Bullous Pemphigoid Induced by DPP-4 Inhibitors. J Invest Dermatol 2017 Dec 2. pii: S0022-202X (17) 33231-1. (doi: 10.1016\/j.jid.2017.11.023). [Epub ahead of print]."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H, et al.: Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci USA 2015; 112: 1809-1814.","DOI":"10.1073\/pnas.1417636112"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Pasmatzi E, Monastirli A, Habeos J, Georgiou S, Tsambaos D: Dipeptidyl peptidase-4 inhibitors cause bullous pemphigoid in diabetic patients: report of two cases. Diabates Care 2011; 34: e113.","DOI":"10.2337\/dc11-0804"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Yoshiji S, Murakami T, Harashima S, Ko R, Kashima R, et al.: Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: A report of five cases. J Diabetes Investig 2018; 9: 445-447.","DOI":"10.1111\/jdi.12695"}],"container-title":["Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/geriatrics\/56\/1\/56_56.43\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T23:21:42Z","timestamp":1550272902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/geriatrics\/56\/1\/56_56.43\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,25]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.3143\/geriatrics.56.43","relation":{},"ISSN":["0300-9173"],"issn-type":[{"value":"0300-9173","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1,25]]}}}